Design, synthesis, and antiangiogenic effects of a series of potent novel fumagillin analogues

Chemical and Pharmaceutical Bulletin

Volumn 55, Issue 7, 2007, Pages 1024-1029

  Lee, Hong Woo ^a   Cho, Chin Sung ^a   Kang, Sung Kwon ^a   Yoo, Yong Sang ^a   Shin, Jae Soo ^a   Ahn, Soon Kil ^a  

^a Chong Kun Dang Research Institute   (South Korea)

Author keywords

Antiangiogenic activity; Aspergillus fumigatus; Hydroxyethoxycinnamoyl fumagillol derivative; Semisynthesis; TNP 470

Indexed keywords

4 HYDROXYETHOXY 3,5 DIMETHOXYFUMAGILLIN; 4 HYDROXYETHOXYCINNAMOYLFUMAGILLIN; ANGIOGENESIS INHIBITOR; CKD 732; FUMAGILLIN; FUMAGILLIN DERIVATIVE; FUMAGILLOL; FUMAGILLOL CHLOROACETYLCARBAMATE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FATTY ACIDS, UNSATURATED; HUMANS; MICE; MOLECULAR STRUCTURE; SESQUITERPENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34447095334     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.55.1024     Document Type: Article

References (20)

1. Folkman J., N. Engl. J. Med., 285, 1182-1186 (1971).
2. Hanahan D., Folkman J., Cell, 86, 353-364 (1996).
3. Zhang H.-T., Harris A. L., Exp. Invest. Drug, 7, 1629-1655 (1998).
4. Hanson T. E., Antibiot. Chemother., 1, 54 (1951).
5. Marui S., Itoh F., Kozai Y., Sudo K., Kishmoto S., Chem. Pharm. Bull., 40, 96-101 (1992).
6. Ingber D., Fujita T., Kishmoto S., Sudo K., Kanamaru T., Brem H., Folkman J., Nature (London), 348, 555-557 (1990).
7. Han C. K., Ahn S. K., Choi N. S., Hong R. K., Moon S. K., Chun H. K., Lee S. J., Kim J. W., Hong C. I., Kim D., Yoon J. H., No K. T., Bioorg. Med. Chem. Lett., 10, 39-43 (2000).
8. Lee H. S., Choi W. K., Son H. J., Lee S. S., Kim J. K., Ahn S. K., Hong C. I., Min H. K., Kim Y. S., Arch. Pharm. Rev., 27, 265-272 (2004).
9. Sin N., Meng L., Wang M. Q., Wen J. J., Bornmann W. G., Crew C. M., Proc. Natl. Acad. Sci. U.S.A., 94, 6099-6103 (1997).
10. Lui S., Widom J., Kemp C. W., Crew C. M., Clardy J., Science, 282, 1324-1327 (1998).
11. Griffith E. C., Su Z., Turk B. E., Chen S., Chang Y.-H., Wu Z., Biemann K., Lui J. O., Chem. Biol., 4, 461-468 (1997).
12. Bhargava P., Marshall J. L., Rizvi N., Dahut W., Yoe J., Clin. Cancer Res., 5, 1989-1995 (1999).
13. Placidi L., Cretton-Scott E., de Sousa G., Rahmani R., Placidi M., Cancer Res., 55, 3036-3042 (1995).
14. Kim D., Min J., Ahn S. K., Lee H. W., Choi N. S., Moon S. K., Chem. Pharm. Bull., 52, 447-450 (2004).
15. Fumagillin purchased by Chong Kun Dang Bio Corp., as raw material kg-base, this raw material stored at cold room (below 4°C).
16. Sedlakova O., Sedlak J., Hunakova L., Jakubikova J., Duraj J., Sulikova M., Chovancova J., Chorvath B., Neoplasma, 45, 283 (1999).
17. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R., J. Natl. Cancer Inst., 82, 1107-1112 (1990).
18. Still W. C., Kahn M., Mitra A., J. Org. Chem., 43, 2923-2925 (1978).
19. Yoon N. M., Park K. B., Gyoung Y. S., Tetrahedron Lett., 24, 5367-5370 (1983).
20. Kabalka G. W., Wadgonkar P. P., Chatla N., Synth. Commun., 20, 293-299 (1990) and reference cited therein.